Aptose Biosciences (APTO) Earning Somewhat Favorable Media Coverage, Report Finds
Press coverage about Aptose Biosciences (NASDAQ:APTO) (TSE:APS) has been trending somewhat positive on Tuesday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aptose Biosciences earned a coverage optimism score of 0.11 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.3249748591592 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- Aptose Biosciences, Inc. (APTO) Given Average Recommendation of “Buy” by Analysts (americanbankingnews.com)
- Aptose To Present New CG’806 Data At The 2017 ASH Annual Meeting (thestreet.com)
- Aptose Biosciences Inc. (APTO) – Technical indicators take into account – Wall Street Morning (wallstreetmorning.com)
- Aptose Biosciences (APTO) to Present New CG’806 Data at ASH (streetinsider.com)
Several equities research analysts have weighed in on APTO shares. Zacks Investment Research upgraded shares of Aptose Biosciences from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a research report on Monday, August 14th. HC Wainwright upgraded shares of Aptose Biosciences from a “neutral” rating to a “buy” rating and raised their price objective for the company from $1.00 to $4.00 in a research report on Thursday, September 7th. Roth Capital restated a “buy” rating and issued a $5.00 price objective on shares of Aptose Biosciences in a research report on Monday, October 23rd. Finally, ValuEngine cut shares of Aptose Biosciences from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. Aptose Biosciences currently has a consensus rating of “Buy” and an average price target of $5.90.
Shares of Aptose Biosciences (APTO) traded down $0.05 during trading hours on Tuesday, hitting $1.61. 148,786 shares of the stock traded hands, compared to its average volume of 293,472. Aptose Biosciences has a 12 month low of $0.78 and a 12 month high of $1.79.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.07. research analysts expect that Aptose Biosciences will post -0.58 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Aptose Biosciences (APTO) Earning Somewhat Favorable Media Coverage, Report Finds” was first posted by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.watchlistnews.com/aptose-biosciences-apto-earning-somewhat-favorable-media-coverage-report-finds/1686127.html.
Aptose Biosciences Company Profile
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.